Correction: Pathogenic LRRK2 Mutations Do Not Alter Gene Expression in Cell Model Systems or Human Brain Tissue.
Main Authors: | Michael J. Devine, Alice Kaganovich, Mina Ryten, Adamantios Mamais, Daniah Trabzuni, Claudia Manzoni, Philip McGoldrick, Diane Chan, Allissa Dillman, Julia Zerle, Susannah Horan, Jan-Willem Taanman, John Hardy, Jose-Felix Marti-Masso, Daniel Healy, Anthony H. Schapira, Benjamin Wolozin, Rina Bandopadhyay, Mark R. Cookson, Marcel P. van der Brug, Patrick A. Lewis |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2012-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC3269322 |
Similar Items
-
Pathogenic LRRK2 mutations do not alter gene expression in cell model systems or human brain tissue.
by: Michael J Devine, et al.
Published: (2011-01-01) -
Differential LRRK2 Signalling and Gene Expression in WT-LRRK2 and G2019S-LRRK2 Mouse Microglia Treated with Zymosan and MLi2
by: Iqra Nazish, et al.
Published: (2023-12-01) -
Divergent α-synuclein solubility and aggregation properties in G2019S LRRK2 Parkinson's disease brains with Lewy Body pathology compared to idiopathic cases
by: Adamantios Mamais, et al.
Published: (2013-10-01) -
Preclinical modeling of chronic inhibition of the Parkinson’s disease associated kinase LRRK2 reveals altered function of the endolysosomal system in vivo
by: Jillian H. Kluss, et al.
Published: (2021-03-01) -
Transcriptome analysis of LRRK2 knock-out microglia cells reveals alterations of inflammatory- and oxidative stress-related pathways upon treatment with α-synuclein fibrils
by: Isabella Russo, et al.
Published: (2019-09-01)